Cellarity Takes Broader, Whole-Cell Approach To Drug Discovery
CEO Fabrice Chouraqui spoke with Scrip about the company’s new $121m financing and its use of machine learning to target the whole cell instead of molecular targets in novel therapies.
CEO Fabrice Chouraqui spoke with Scrip about the company’s new $121m financing and its use of machine learning to target the whole cell instead of molecular targets in novel therapies.